Genetics and Environment iNtersection In the ALS-FTD Spectrum: an Italian Twins Cohort studY With a Multi-Omics Approach

ALS, FTD

ALS, FTD, twin, cohort

The goal of this study is to learn from discordant twins affected by Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia the contribution of genetic background versus environmental exposure. The main questions it aims to answer is: * How far does the genetic background explain the onset of ALS/FTD in discordant twins? * Which environmental factors and events occurring in post-fetal life influence the onset or progression of this neurodegenerative condition? Participants with ALS and/or FTD with a monozygotic or dizygotic twin willing to contribute to this research will be followed up for two years by specialized Motor Neuron Disorders centers in Italy, donating biological specimen for -omic sciences analysis, and checking out if prodromal signs/symptoms of these two conditions will develop during time.

The main objective of the study is to develop a prospective national twins cohort and virtual biobank collecting demographic, clinical and instrumental data and biological samples of twins with ALS/FTD. Through the definition of a multi-omics profile in ALS twins the study aims to disclose the burden of environmental or genetic risk factors for ALS/FTD and ALS specific biological signatures. Secondary aims include: * to disclose part of the heritability gap in monozygotic (MZ) discordant twins * to assess the burden of epigenetic and transcriptomic differences between MZ discordant twins, uncovering which pathways are activated/inactivated in asymptomatic twins and may protect them from the neurodegenerative process * to evaluate the effects of environment on the risk of developing ALS/FTD (discordant twins) and of developing different phenotypes of ALS (concordant twins). Exposure history will be related to quantification of pesticides, heavy metals and metalloids in biological samples. * to investigate how lifetime environmental exposures affect microbiota composition and next metabolomics and immune profile * to correlate biological signatures with clinical features and disease heterogeneity (onset, progression, survival) for discordant twins * to correlate environmental factors exposure with biological factors as mentioned above (e.g.microbiota, immunological. factors) * to acquire biological data over time to discriminate between changes related to disease pathogenesis and epiphenomena secondary to the disease advancement. * to assess neurophysiological, neuropsychological and imaging signatures within the ALS-FTD spectrum of disease across discordant twins, in particular in the asymptomatic twin, in order to disclose potential presymptomatic subclinical traits. In concordant twins, the same extensive batteries will be used to evaluate whether disease progression proceeds at the same pace or affects similar or divergent neuroanatomical substrates. Study population Being a national ALS-FTD twin cohort study, study population could include all Italian MZ and dizygotic (DZ) twins of whom at least one is affected by ALS or ALS-FTD and possibly their parents for trios studies. ALS/FTD twins will be invited from the referring neurologist to participate in the GENIALITY study and will be sent for screening and baseline visits to the nearest clinical center involved in this study, either Modena, Turin or Palermo. Twin pairs will undergo a detailed interview, visit, clinical tests including neuropsychological testing (NPS), neuroimaging and neurophysiological studies, extensive environmental and exposure history, and blood, CSF (optional), skin, hair, saliva and stool collection. ALS patients will be followed up by the centers with visits scheduled every 3-4 months as for clinical practice, while healthy twins will be asked to be followed with neurological evaluations every 6 months up to 24 months of the study duration. Twins and parents (optional) will be asked to undergo a detailed interview, neurological examination, samples collection (parent-offspring trios studies) including blood sample, saliva and faeces una tantum. Standard Operating Procedures (SOPs) for sampling, biobanking, clinical, and imaging studies will be shared by all the centers involved in the consortium. SOPs will include requirements for collection, analysis and storage of biological materials and guidelines concerning the shipping of the samples from one center to another, but also guideline concerning the patients' recruitment, informed consent collection, clinical scales, questionnaires administration. Furthermore, a battery of NPS tests will be shared with centers, as well as methods for neurophysiological assessment and requirements for imaging studies (brain MRI and PET). This project will generate multi-omics parameters and correlated demographic and clinical data in ALS/FTD patients, their co-twins and possibly their parents. Data collected from interviewers, medical record review, and laboratory data, will be recorded in online case report forms.

No related papers found yet.

Italy